Clearmind Medicine (Nasdaq: CMND) hits CMND-100 Phase I/II milestone

Rhea-AI Filing Summary

Clearmind Medicine reports a key clinical milestone, completing treatment for all participants in Part A of its Phase I/II trial of CMND-100 for Alcohol Use Disorder. All 24 participants across four cohorts finished treatment according to protocol, and the company is now reviewing the data.

If results remain favorable, Clearmind plans to start the next stage of the Alcohol Use Disorder clinical program. The multicenter, FDA-regulated study is running at leading sites in the United States and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

Clearmind is a clinical-stage biotech focused on non-hallucinogenic, second-generation neuroplastogen-derived therapeutics for under-treated conditions such as Alcohol Use Disorder. Its intellectual property portfolio includes nineteen patent families and 32 granted patents, supporting the development of CMND-100 and other candidates.

Key Figures

Part A participants: 24 participants Cohorts in Part A: 4 cohorts Patent families: 19 patent families +1 more

4 metrics

Part A participants 24 participants Completed treatment in Phase I/II CMND-100 Alcohol Use Disorder trial

Cohorts in Part A 4 cohorts Cohorts 1 through 4 in CMND-100 Phase I/II trial

Patent families 19 patent families Clearmind intellectual property portfolio

Granted patents 32 granted patents Clearmind intellectual property portfolio

Key Terms

Phase I/II clinical trial, Alcohol Use Disorder, neuroplastogen-derived therapeutics, forward-looking statements, +1 more

5 terms

Phase I/II clinical trial medical

"ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder"

A Phase I/II clinical trial is a combined early-stage study that first checks whether a new drug or treatment is safe for people and then looks for initial signs that it works. Think of it as a safety inspection followed by a short test drive: researchers monitor side effects, appropriate dosing, and early effectiveness. For investors, results from these trials matter because they reduce scientific uncertainty and can significantly change a development program’s value and the likelihood of later regulatory approval.

Alcohol Use Disorder medical

"Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD)"

A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.

neuroplastogen-derived therapeutics medical

"non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems"

Neuroplastogen-derived therapeutics are drugs or biological treatments developed from compounds that promote neuroplasticity — the brain’s ability to rewire and form new connections after injury or in response to learning. For investors, they matter because these therapies target underlying brain repair mechanisms rather than only masking symptoms, offering the potential for durable benefits in conditions like depression, stroke recovery, or neurodegeneration; if effective, they can create large, high-value markets similar to replacing a faulty bridge with a stronger one.

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

clinical-stage biotech company financial

"a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/22/2026 - 08:08 AM Accepted by SEC EDGAR 06/22/2026 - 08:08 AM Learn about SEC filing dates

FAQ

What milestone did Clearmind Medicine (CMND) announce in its CMND-100 trial?

Clearmind Medicine completed treatment for all 24 participants in Part A of its Phase I/II CMND-100 trial for Alcohol Use Disorder. The company is assessing the data and, if results stay favorable, plans to begin the next clinical stage in Alcohol Use Disorder patients.

What is CMND-100 and what condition is Clearmind Medicine (CMND) targeting?

CMND-100 is Clearmind Medicine’s investigational, non-hallucinogenic, neuroplastogen-derived therapeutic being evaluated for Alcohol Use Disorder. It is in an FDA-regulated Phase I/II trial, with Part A treatment now completed, as the company works to advance it as a potential alcohol use disorder therapy.

How many patients were treated in Part A of Clearmind Medicine’s CMND-100 trial?

Part A of Clearmind Medicine’s Phase I/II trial enrolled 24 participants across Cohorts 1 through 4. All 24 completed treatment according to the clinical protocol, and the company is reviewing this dataset to guide progression to the next stage of Alcohol Use Disorder clinical development.

Where is Clearmind Medicine’s CMND-100 Alcohol Use Disorder trial being conducted?

The CMND-100 trial is a multicenter study under FDA oversight at leading sites in the United States and Israel. Participating centers include Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, reflecting broad academic collaboration.

What intellectual property does Clearmind Medicine (CMND) report supporting its pipeline?

Clearmind Medicine reports an intellectual property portfolio consisting of nineteen patent families and 32 granted patents. The company intends to seek additional patents and pursue opportunistic intellectual property acquisitions to support its neuroplastogen-derived therapeutics, including CMND-100 for Alcohol Use Disorder and other future candidates.

What forward-looking plans did Clearmind Medicine outline for CMND-100?

Clearmind Medicine plans, assuming favorable data, to initiate the next stage of its Alcohol Use Disorder clinical program with CMND-100. Management stated they aim to progress to the next phase of development and continue advancing CMND-100 as a promising therapeutic candidate, subject to clinical results and risks.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: June 2026

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on June 22, 2026, titled “Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA-Regulated Phase I/II Trial”.

The first, second, third and fifth paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA-Regulated Phase I/II Trial”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: June 22, 2026	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

Exhibit 99.1

 

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA-Regulated Phase I/II Trial

Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).

All 24 participants across Cohorts 1 through 4 have successfully completed treatment according to the study protocol.

The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in Alcohol Use Disorder patients.

“We are pleased to have successfully completed treatment for all participants in Part A of the study, fully aligned with the clinical protocol,” said Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine. “This achievement reflects the dedication of our clinical teams and the value of our partnerships with world-class research centers across the United States and Israel. With data review now underway, we are eager to progress to the next phase of development and continue advancing CMND-100 as a promising therapeutic candidate for Alcohol Use Disorder.”

The multicenter trial is being conducted under FDA oversight (at leading sites in the United States and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trial, how the Company is currently assessing the dataset and, assuming results remain favorable, its intension to initiate the next stage of the clinical program in Alcohol Use Disorder patients, progressing to the next phase of development and continuing to advance CMND-100 as a promising therapeutic candidate for Alcohol Use Disorder. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "CLEARMIND MEDICINE REACHES MAJOR MILESTONE, COMPLETING PA 10.1 KB